DSM Asset Purchase Agreement (Details Textual) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
DSM Asset Purchase Agreement (Textual) [Abstract]
Number of dedicated full time equivalents for new gene libraries		$ 3
Period for which DSM to be provided with FTEs for new gene libraries developed		1 year
Aggregate consideration received by the company		37,000,000
Reimbursement for transaction related expenses incurred		2,000,000
Restricted Period of company global activities In oilseed processing		10 years
Soliciting for employment or hiring		10 years
Termination or expiration period of the transition services agreement		1 year
Gain on sale of oilseed processing business		31,278,000
Decrease in gain on sale of oilseed business due to finalization of arrangements		200,000
Increase in deferred revenue due to finalization of arrangement		200,000
Allocated license revenue for alpha-amylase and xylanase enzyme		(1,520,000)
Cash received and revenue allocated to the non delivered items		1,342,000
Amount recognized as revenue for DSM asset purchase agreement	400,000	1,000,000
Deferred revenue balance	$ 800,000	$ 800,000